1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2022, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 2, 14, 19, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 3 molecules, respectively.
Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Anaplastic Astrocytoma - Overview
- Anaplastic Astrocytoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Anaplastic Astrocytoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anaplastic Astrocytoma - Companies Involved in Therapeutics Development
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AbbVie Inc
- Aettis Inc
- AngioChem Inc
- Apexigen Inc
- Bayer AG
- Berg LLC
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- Candel Therapeutics Inc
- CDG Therapeutics Inc
- Cellix Bio Pvt Ltd
- Chimerix Inc
- Cothera Bioscience Pty Ltd
- Curis Inc
- Everfront Biotech Inc
- Fore Biotherapeutics Inc
- Geneos Therapeutics Inc
- Ipsen SA
- Karyopharm Therapeutics Inc
- Kazia Therapeutics Ltd
- Merck KGaA
- MimiVax LLC
- Mustang Bio Inc
- Nascent Biotech Inc
- Novartis AG
- OncoSynergy Inc
- Orbus Therapeutics Inc
- Orphelia Pharma SAS
- Otsuka Pharmaceutical Co Ltd
- Pfizer Inc
- PTC Therapeutics Inc
- TheraBiologics Inc
- Wayshine Biopharma Inc
- Wuhan Binhui Biotechnology Co Ltd
- Anaplastic Astrocytoma - Drug Profiles
- afatinib dimaleate - Drug Profile
- Product Description
- Mechanism Of Action
- aglatimagene besadenovec - Drug Profile
- Product Description
- Mechanism Of Action
- BAY-1436032 - Drug Profile
- Product Description
- Mechanism Of Action
- BAY-2666605 - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Cellular Immunotherapy for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- CLXONC-643 - Drug Profile
- Product Description
- Mechanism Of Action
- dabrafenib mesylate - Drug Profile
- Product Description
- Mechanism Of Action
- eflornithine - Drug Profile
- Product Description
- Mechanism Of Action
- fimepinostat - Drug Profile
- Product Description
- Mechanism Of Action
- FORE-8394 - Drug Profile
- Product Description
- Mechanism Of Action
- futibatinib - Drug Profile
- Product Description
- Mechanism Of Action
- G-207 - Drug Profile
- Product Description
- Mechanism Of Action
- GENPV-001 - Drug Profile
- Product Description
- Mechanism Of Action
- irinotecan hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- M-032 - Drug Profile
- Product Description
- Mechanism Of Action
- MB-108 - Drug Profile
- Product Description
- Mechanism Of Action
- MB-110 - Drug Profile
- Product Description
- Mechanism Of Action
- OH-2 - Drug Profile
- Product Description
- Mechanism Of Action
- ON-01 - Drug Profile
- Product Description
- Mechanism Of Action
- ONC-206 - Drug Profile
- Product Description
- Mechanism Of Action
- OS-2966 - Drug Profile
- Product Description
- Mechanism Of Action
- P-28 - Drug Profile
- Product Description
- Mechanism Of Action
- paclitaxel trevatide - Drug Profile
- Product Description
- Mechanism Of Action
- palbociclib - Drug Profile
- Product Description
- Mechanism Of Action
- paxalisib - Drug Profile
- Product Description
- Mechanism Of Action
- pritumumab - Drug Profile
- Product Description
- Mechanism Of Action
- regorafenib - Drug Profile
- Product Description
- Mechanism Of Action
- ribociclib succinate - Drug Profile
- Product Description
- Mechanism Of Action
- selinexor - Drug Profile
- Product Description
- Mechanism Of Action
- SL-701 - Drug Profile
- Product Description
- Mechanism Of Action
- sorafenib tosylate - Drug Profile
- Product Description
- Mechanism Of Action
- sotigalimab - Drug Profile
- Product Description
- Mechanism Of Action
- SurVaxM - Drug Profile
- Product Description
- Mechanism Of Action
- TBX.OncV NSC - Drug Profile
- Product Description
- Mechanism Of Action
- telaglenastat hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- temozolomide - Drug Profile
- Product Description
- Mechanism Of Action
- tepotinib hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- trotabresib - Drug Profile
- Product Description
- Mechanism Of Action
- ubidecarenone - Drug Profile
- Product Description
- Mechanism Of Action
- unesbulin - Drug Profile
- Product Description
- Mechanism Of Action
- veliparib ER - Drug Profile
- Product Description
- Mechanism Of Action
- WSD-0922 - Drug Profile
- Product Description
- Mechanism Of Action
- z-90099 - Drug Profile
- Product Description
- Mechanism Of Action
- zotiraciclib citrate - Drug Profile
- Product Description
- Mechanism Of Action
- Anaplastic Astrocytoma - Dormant Projects
- Anaplastic Astrocytoma - Discontinued Products
- Anaplastic Astrocytoma - Product Development Milestones
- Featured News & Press Releases
- Jan 19, 2022: Orbus Therapeutics’ phase 3 Eflornithine STELLAR study reaches full patient enrollment
- Sep 28, 2021: Orbus Therapeutics granted European patent for method of use for Eflornithine
- Mar 02, 2021: Orbus Therapeutics announces positive outcome of pre-planned interim futility analysis for phase 3 Eflornithine STELLAR study
- Dec 23, 2020: Orbus Therapeutics receives U.S. Patent for Eflornithine formulations
- Jul 10, 2020: Geneos Therapeutics announces first patient dosed with its DNA-based, neoantigen-targeting personalized vaccine technology
- Feb 04, 2020: STELLAR clinical trial of eflornithine to enrol brain tumour patients
- May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019
- Jun 05, 2017: Orbus Therapeutics Announces ASCO Study Design Presentation of Pivotal Clinical Trial in Patients with Late-Stage Brain Cancer
- Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Anaplastic Astrocytoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Anaplastic Astrocytoma - Dormant Projects, 2022
- Anaplastic Astrocytoma - Discontinued Products, 2022
- Number of Products under Development for Anaplastic Astrocytoma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AbbVie Inc
- Aettis Inc
- AngioChem Inc
- Apexigen Inc
- Bayer AG
- Berg LLC
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- Candel Therapeutics Inc
- CDG Therapeutics Inc
- Cellix Bio Pvt Ltd
- Chimerix Inc
- Cothera Bioscience Pty Ltd
- Curis Inc
- Everfront Biotech Inc
- Fore Biotherapeutics Inc
- Geneos Therapeutics Inc
- Ipsen SA
- Karyopharm Therapeutics Inc
- Kazia Therapeutics Ltd
- Merck KGaA
- MimiVax LLC
- Mustang Bio Inc
- Nascent Biotech Inc
- Novartis AG
- OncoSynergy Inc
- Orbus Therapeutics Inc
- Orphelia Pharma SAS
- Otsuka Pharmaceutical Co Ltd
- Pfizer Inc
- PTC Therapeutics Inc
- TheraBiologics Inc
- Wayshine Biopharma Inc
- Wuhan Binhui Biotechnology Co Ltd
